Mechanisms of Bromocriptine-Induced Hallucinations

New England Journal of Medicine

Volumn 302, Issue 26, 1980, Pages 1479-

  Goodkin, David A ^a   Parkes, David ^b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; LYSERGIDE;

ADVERSE DRUG REACTION; EDITORIAL; ETIOLOGY; HALLUCINATION; PATHOGENESIS;

BROMOCRIPTINE; HALLUCINATIONS; HUMAN;

EID: 0019154777     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198006263022614     Document Type: Letter

References (11)

1. Cerletti A, Doepfner W. Comparative study on the serotonin antagonism of amide derivatives of lysergic acid and of ergot alkaloids. J Pharmacol Exp Ther. 1958; 122: 124–36.
2. Solms H. Relationships between chemical structure and psychoses with the use of psychotoxic substances. J Clin Exp Psychopathol. 1956; 17: 429–33.
3. Hoffer A. D-Lysergic acid diethylamide (LSD): a review of its present status. Clin Pharmacol Ther. 1965; 6: 183–255.
4. Appel J, Freedman D. The relative potencies of psychotomimetic drugs. Life Sci. 1965; 4: 2181–6.
5. Meltzer H, Stahl S. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976; 2: 19–76.
6. Fanchamps A. Some compounds with hallucinogenic activity. In: Berde B, Schild O, eds. Ergot alkaloids and related compounds. Berlin: Springer-Verlag, 1978:596.
7. Flückiger E. Ergots and endocrine functions. In: Goldstein et al, eds. Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. New York: Raven Press, 1980:155–63.
8. Godwin-Austen RB. Levodopa compared with bromocriptine in the treatment of Parkinson's disease. In: Goldstein et al. eds. Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. New York: Raven Press, 1980:261–5.
9. Stern GM, Lees AJ, Shaw KM, Larder CM. The role of bromocriptine in the treatment of Parkinson's disease. In: Goldstein et al, eds. Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. New York: Raven Press, 1980:267–0.
10. Duvoisin RC, Mendoza MM, Yahr MD. A comparative study of bromocriptine in Parkinson's disease. In: Goldstein et al, eds. Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. New York: Raven Press, 1980:271–5.
11. Parkes JD, Debono AG, Marsden CD. Bromocriptine in parkinsonism: long-term treatment, dose response, and comparison with levodopa. J Neurol Neurosurg Psychiatry. 1976; 39: 1101–7.